Owing to increasing resistance and the limited arsenal of new antibiotics, especially against Gram-negative pathogens, carefully designed antibiotic regimens are obligatory for febrile neutropenic patients, along with effective infection control. The Expert Group of the 4(th) European Conference on Infections in Leukemia has developed guidelines for initial empirical therapy in febrile neutrope...

Background It is well known that patients with severe neutropenia are susceptible to bacterial infections, which may become lifethreatening. This hematologic disorder frequently occurs as an adverse effect of certain drug therapies. One of them, currently encountered in practice, is therapy with antithyroid drugs. An infective source is identified in average in 20-30% of febrile neutropenia epi...

Febrile neutropenia (FN) is characterized by a decrease in neutrophils number to values below 500 cells/ mm3 and an occurrence of fever higher or similar to38.3oC. It commonly occurs in cancer patients as a result of chemotherapy regimens. Chemotherapy destroys carcinogenic cells but also attacks in many cases some normal cells including essential elements of the immune system. Fever is one of ...

Febrile neutropenia is common chemotherapy complication significantly impacting patient's outcomes, quality of life and costs, too. Febrile neutropenia (FN) often leads to hospitalization, the need for intravenous antibiotics and use of granulocyte colony-stimulating factors (GCSF) in order to avoid its complications. Cost of febrile neutropenia is well described in literature, but no study has...

The purpose of this study is to determine whether, in low-risk febrile neutropenic paediatric populations, oral antibiotics are as effective as intravenous antibiotics in obtaining resolution of the febrile neutropenic episode. A comprehensive literature search of MEDLINE, EMBASE and CENTRAL identified prospective, randomised controlled trials comparing oral antibiotics with intravenous antibio...

We evaluated pentraxin 3 as a marker for complications of neutropenic fever in 100 hematologic patients receiving intensive chemotherapy. Pentraxin 3 and C-reactive protein were measured at fever onset and then daily to day 3. Bacteremia was observed in 19 patients and septic shock in 5 patients (three deaths). In comparison to C-reactive protein, pentraxin 3 achieved its maximum more rapidly. ...

background: granulocyte colony stimulating factors (gcsf) are high cost agents commonly recommended for primary and secondary prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia. gcsfs have been shown to be beneficial in some patient subgroups, although they are probably overused in clinical settings. the american society of clinical oncology (asco) guidelines summarize curr...

BACKGROUND Despite major advances in its prevention and treatment, febrile neutropenia remains a most concerning complication of cancer chemotherapy. Outside the oncology setting, however, only few data are currently available on febrile neutropenia related to non-chemotherapy drugs. We report here data on 76 patients with febrile neutropenia related to non-chemotherapy drugs, followed up in a ...

Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44%) did not receive antifungal prophylaxis; 835 (28%) received poorly absorbable antifungal agents and 845 (28%) received absorbable antifungal ...